Ratio Therapeutics Partners with Novartis to Advance SSTR2-Targeting Radiotherapeutic Candidate for Cancer
Shots:
- Ratio Therapeutics has entered into an exclusive worldwide licensing and collaboration agreement with Novartis for the development of SSTR2-targeting radiotherapeutic candidate for cancer treatment
- The alliance will employ Ratio's radioligand discovery & development expertise as well as technology with Novartis' strengths to enhance safety & efficacy for patients
- As per the agreement, Ratio will receive up to $745M upfront & milestones plus tiered royalties. It will lead preclinical research to select an SSTR2-targeting candidate, while Novartis will handle further development, manufacturing & commercialization
Ref: PR Newswire | Image: Novartis & Ratio Therapeutics
Related News:- Schrödinger Enters into a Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
